Liquidia (NASDAQ:LQDA) Stock

LIQUIDIA CORP

Liquidia

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Liquidia Corp

News

Management

FELE

Franklin Electric Appoints Jennifer Wolfenbarger As CFO

Keybanc analyst Jason Celino maintains Bentley Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSY#NASDAQ">BSY</a>) with a Overweight and raises the price target from $56 to $59.

Price Target

Analyst Ratings

Keybanc Maintains Overweight on Bentley Systems, Raises Price Target to $59

Keybanc analyst Michael Leshock initiates coverage on Voyager Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOYG#NYSE">VOYG</a>) with a Overweight rating and announces Price Target of $50.

Initiation

VOYG

Keybanc Initiates Coverage On Voyager Technologies with Overweight Rating, Announces Price Target of $50

HC Wainwright &amp; Co. analyst Emily Bodnar maintains Jasper Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) with a Buy and lowers the price target from $40 to $20.

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

HC Wainwright & Co. Maintains Buy on Jasper Therapeutics, Lowers Price Target to $20

Offerings

GAME

GameSquare Reveals Proposed Public Offering of Common Stock; Size Not Disclosed

<a href="https://truthsocial.com/@realDonaldTrump/posts/114813877378281211" title="https://truthsocial.com/@realDonaldTrump/posts/114813877378281211">https://truthsocial.com/@realDonaldTrump/posts/114813877378281211</a>

Macro Economic Events

Politics

Economics

General

President Trump Says U.S. Will Impose 36% Tariff On Thailand

Carpenter Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRS#NYSE">CRS</a>) has outperformed the market over the past 20 years by 3.68% on an annualized basis producing an average annual return of 12.12%. Currently, Carpenter Tech has a market capitalization of $13.97 billion. 
Buying $1000 In CRS: If an investor had bought $1000 of CRS stock 20 years ago, it would be worth $9,784.94 today based on a price of $280.73 for CRS at the time of writing.
<h3>Carpenter Tech's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751921113_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $1000 Invested In Carpenter Tech 20 Years Ago Would Be Worth Today

HC Wainwright &amp; Co. analyst Heiko Ihle maintains Northern Dynasty Minerals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NAK#AMEX">NAK</a>) with a Buy and raises the price target from $1.3 to $2.5.

HC Wainwright & Co. Maintains Buy on Northern Dynasty Minerals, Raises Price Target to $2.5

<a href="https://truthsocial.com/@realDonaldTrump/114813871213779514">https://truthsocial.com/@realDonaldTrump/114813871213779514</a>

Macro Notification

President Trump Says U.S. Will Impose 36% Tariff On Cambodia

<a href="https://truthsocial.com/@realDonaldTrump/posts/114813868233643692" title="https://truthsocial.com/@realDonaldTrump/posts/114813868233643692">https://truthsocial.com/@realDonaldTrump/posts/114813868233643692</a>

Government

President Trump Says U.S. Will Impose A 35% Tariff On Serbia

<a href="https://truthsocial.com/@realDonaldTrump/114813866366780377">https://truthsocial.com/@realDonaldTrump/114813866366780377</a>

President Trump Says U.S. Will Impose 35% Tariff On Bangladesh

<a href="https://truthsocial.com/@realDonaldTrump/posts/114813864598173973" title="https://truthsocial.com/@realDonaldTrump/posts/114813864598173973">https://truthsocial.com/@realDonaldTrump/posts/114813864598173973</a>

President Trump Says U.S. Will Impose 32% Tariff On Indonesia

HC Wainwright &amp; Co. analyst Scott Buck maintains Intrusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) with a Neutral and raises the price target from $1.5 to $2.5.

INTZ

HC Wainwright & Co. Maintains Neutral on Intrusion, Raises Price Target to $2.5

<a href="https://truthsocial.com/@realDonaldTrump/posts/114813863196329189">https://truthsocial.com/@realDonaldTrump/posts/114813863196329189</a>

President Trump Says U.S. Will Impose 30% Tariff On Bosnia and Herzegovina

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth assumes Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) with a Neutral rating and announces Price Target of $1.5.

AEMD

HC Wainwright & Co. Assumes Aethlon Medical at Neutral, Announces Price Target of $1.5

PBBK

Trading Halt: Halt status updated at 4:40:00 PM ET: Quotation Resumption: News and Resumption Times

WIIM

APDN

Applied DNA Sciences shares are trading higher after the company announced it regained Nasdaq compliance.

LASE

Laser Photonics shares are trading higher after the company reported a year-over-year increase in Q1 revenue results.

Greenridge Global analyst William Gregozeski initiates coverage on MoneyHero (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNY#NASDAQ">MNY</a>) with a Buy rating and announces Price Target of $4.

Greenridge Global Initiates Coverage On MoneyHero with Buy Rating, Announces Price Target of $4

Global

South Korea Says Will Step Up Trade Negotiations With The US To Win Mutually Beneficial Results And Clear Up Uncertainties Caused By Tariffs

Press Releases

UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference

Earnings

Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025

Health Care

Legal

District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia

Liquidia Corporation to Present at BofA Securities 2025 Health Care Conference

Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update

Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics

U.S. FDA Approves Liquidia's YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Comments

Liquidia

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL